US trial set for noninvasive fertility monitor:
This article was originally published in Clinica
Pheromone Sciences is to begin a multicentre, 140-patient clinical trial of its noninvasive PSC Fertility Monitor in the US. Researchers will compare the device, which predicts ovulation by measuring ion changes on the skin's surface, with current techniques for detecting fertility and ovulation. The Toronto, Ontario-based company already has marketing clearance for the device in Canada. It plans to submit a US marketing application for the test by the end of the year.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.